25 August 2020 – Sulzer Ltd has agreed to acquire the Swiss-German Haselmeier Group for an enterprise value of EUR 100 million. Closing of the transaction is planned for the fourth quarter of 2020.

Haselmeier is a leading provider of patented injection systems such as subcutaneous self-injection pens for use in fast growing indications such as reproductive health, growth disorders, osteoporosis and diabetes.

Sulzer is a global leader in fluid engineering, specializing in pumping, stirring, mixing, separation and application technologies for all types of fluids. Sulzer employs 16,500 employees worldwide, operates 180 production and service sites and generated sales of CHF 3.7 billion in 2019. With the acquisition of Haselmeier, Sulzer will complement its healthcare portfolio and leverage its APS expertise in precision injection molding to seize growth opportunities in the fast-growing drug delivery devices market.

Walder Wyss (lead counsel) has advised Sulzer together with the German law firm Gleiss Lutz and further foreign law firms. The Walder Wyss team was led by Markus Vischer (Partner, Corporate/M&A), Claudia Weber (Senior Associate, Corporate/M&A) and Nico Bernhard (Associate, Corporate/M&A) and further included Dimitrios Berger (Associate, Corporate/M&A), Christine Schweikard (Associate, IP/IT) and Jasmin Eicher (Junior Associate, Corporate/M&A).